Prelude Therapeutics

0.71
-0.08 (-9.81%)
At close: Apr 03, 2025, 3:59 PM
0.72
1.69%
After-hours: Apr 03, 2025, 05:43 PM EDT

Prelude Therapeutics Statistics

Share Statistics

Prelude Therapeutics has 55.15M shares outstanding. The number of shares has increased by 0.41% in one year.

Shares Outstanding 55.15M
Shares Change (YoY) 0.41%
Shares Change (QoQ) 0.22%
Owned by Institutions (%) 42.4%
Shares Floating 34.37M
Failed to Deliver (FTD) Shares 75
FTD / Avg. Volume 0.03%

Short Selling Information

The latest short interest is 3.12M, so 5.66% of the outstanding shares have been sold short.

Short Interest 3.12M
Short % of Shares Out 5.66%
Short % of Float 11.03%
Short Ratio (days to cover) 4.53

Valuation Ratios

The PE ratio is -0.76 and the forward PE ratio is -0.76. Prelude Therapeutics's PEG ratio is 0.04.

PE Ratio -0.76
Forward PE -0.76
PS Ratio 13.75
Forward PS 0.4
PB Ratio 0.73
P/FCF Ratio -0.93
PEG Ratio 0.04
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Prelude Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 5.3, with a Debt / Equity ratio of 0.14.

Current Ratio 5.3
Quick Ratio 5.3
Debt / Equity 0.14
Debt / EBITDA -0.13
Debt / FCF -0.17
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $53.44K
Profits Per Employee $-970.79K
Employee Count 131
Asset Turnover 0.04
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -83.26% in the last 52 weeks. The beta is 1.42, so Prelude Therapeutics's price volatility has been higher than the market average.

Beta 1.42
52-Week Price Change -83.26%
50-Day Moving Average 0.88
200-Day Moving Average 2.38
Relative Strength Index (RSI) 51.76
Average Volume (20 Days) 238.85K

Income Statement

In the last 12 months, Prelude Therapeutics had revenue of 7M and earned -127.17M in profits. Earnings per share was -1.68.

Revenue 7M
Gross Profit 7M
Operating Income -139.71M
Net Income -127.17M
EBITDA -139.71M
EBIT -139.71M
Earnings Per Share (EPS) -1.68
Full Income Statement

Balance Sheet

The company has 12.47M in cash and 18.02M in debt, giving a net cash position of -5.55M.

Cash & Cash Equivalents 12.47M
Total Debt 18.02M
Net Cash -5.55M
Retained Earnings -583.56M
Total Assets 175.51M
Working Capital 110.25M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -102.89M and capital expenditures -764K, giving a free cash flow of -103.65M.

Operating Cash Flow -102.89M
Capital Expenditures -764K
Free Cash Flow -103.65M
FCF Per Share -1.37
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -1995.91% and -1816.76%.

Gross Margin 100%
Operating Margin -1995.91%
Pretax Margin -1816.76%
Profit Margin -1816.76%
EBITDA Margin -1995.91%
EBIT Margin -1995.91%
FCF Margin -1480.74%

Dividends & Yields

PRLD does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for PRLD is $4, which is 406.3% higher than the current price. The consensus rating is "Buy".

Price Target $4
Price Target Difference 406.3%
Analyst Consensus Buy
Analyst Count 3
Stock Forecasts

Scores

Altman Z-Score -5.91
Piotroski F-Score 3